BDRX — Biodexa Pharmaceuticals Balance Sheet
0.000.00%
- $2.66m
- -$4.30m
- £0.38m
Annual balance sheet for Biodexa Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 10.9 | 7.55 | 10.1 | 2.84 | 5.97 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2.81 | 1.47 | 1.1 | 1.48 | 0.704 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 13.7 | 9.28 | 11.8 | 4.69 | 7.03 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.15 | 0.542 | 1.15 | 0.831 | 0.571 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Notes Receivable | |||||
Total Assets | 30.9 | 9.82 | 12.9 | 5.53 | 10.5 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 5.67 | 2.99 | 1.84 | 1.9 | 5.57 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 11.3 | 3.1 | 2.46 | 2.36 | 5.86 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 19.6 | 6.72 | 10.5 | 3.16 | 4.68 |
Total Liabilities & Shareholders' Equity | 30.9 | 9.82 | 12.9 | 5.53 | 10.5 |
Total Common Shares Outstanding |